<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121376</url>
  </required_header>
  <id_info>
    <org_study_id>331-201</org_study_id>
    <nct_id>NCT05121376</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Safety, Tolerability &amp; Efficacy Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema</brief_title>
  <acronym>HAErmony-1</acronym>
  <official_title>A Phase 1/2 Open-Label, Dose-Escalation Study to Determine the Safety Tolerability &amp; Efficacy of BMN 331 an AAV Vector-Mediated Gene Transfer of Human SERPING1 Gene in Subjects With HAE Due to Human C1-INH Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN&#xD;
      331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH)&#xD;
      protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an&#xD;
      adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1&#xD;
      Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being&#xD;
      developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331&#xD;
      is a solution for intravenous infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BMN 331 is an investigational, single administration gene therapy intended to modify the&#xD;
      disease course of HAE. Preclinical studies have shown that BMN 331 can transduce hepatocytes&#xD;
      resulting in restoration of the deficient circulating levels of hC1-INH that cause HAE.&#xD;
&#xD;
      Study 331-201 is a two-part (part A and part B), first-in-human, Phase 1/2 study designed to&#xD;
      assess the safety and efficacy of BMN 331 in patients with HAE. Subjects will be followed for&#xD;
      5 years following BMN 331 infusion. Part A of the study is a dose escalation phase designed&#xD;
      to assess the preliminary safety of a single IV administration of BMN 331 and to determine&#xD;
      whether there is a dose-dependent increase in C1-INH protein expression following&#xD;
      administration of BMN 331. Part B is a dose expansion phase designed to demonstrate that up&#xD;
      to three safe doses of BMN 331 (as determined in Part A) sustains a clinically meaningful&#xD;
      increase in C1-INH levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2028</completion_date>
  <primary_completion_date type="Anticipated">November 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-emergent adverse events following a single IV administration of BMN 331</measure>
    <time_frame>At 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of investigator-confirmed HAE attacks</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized use of HAE medication</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of functional C1-INH following BMN-331 infusion</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of C1-INH antigen following BMN 331 infusion</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of total antibodies against AAV5 capsid following BMN 331 infusion</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of total antibodies against C1-INH following BMN 331 infusion</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of neutralizing antibodies against C1-INH following BMN 331 infusion</measure>
    <time_frame>At 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hereditary Angioedema</condition>
  <condition>HAE</condition>
  <arm_group>
    <arm_group_label>BMN 331</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AAV Gene Therapy Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Dose 1 of BMN 331</intervention_name>
    <description>BMN 331 AAV Gene Therapy</description>
    <arm_group_label>BMN 331</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Dose 2 of BMN 331</intervention_name>
    <description>BMN 331 AAV Gene Therapy</description>
    <arm_group_label>BMN 331</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Dose 3 of BMN 331</intervention_name>
    <description>BMN 331 AAV Gene Therapy</description>
    <arm_group_label>BMN 331</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Dose 4 of BMN 331</intervention_name>
    <description>BMN 331 AAV Gene Therapy</description>
    <arm_group_label>BMN 331</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Dose 5 of BMN 331</intervention_name>
    <description>BMN 331 AAV Gene Therapy</description>
    <arm_group_label>BMN 331</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female or male adults ( â‰¥ 18 years old)&#xD;
&#xD;
          2. Confirmed diagnosis of HAE due to C1-INH deficiency (Type I or II) confirmed by&#xD;
             genotyping of SERPING1 gene&#xD;
&#xD;
          3. Currently using an HAE medication regimen that consists of a routine long-term&#xD;
             prophylactic treatment or an on-demand therapy for the last 6 months prior to&#xD;
             enrollment for a documented attack frequency of at least 1 attack per month on average&#xD;
&#xD;
          4. Trained in self-administering acute attack treatment and is able to adequately manage&#xD;
             acute attacks in a home setting&#xD;
&#xD;
          5. Willingness to abstain from consumption of alcohol for at least 52 weeks post BMN 331&#xD;
             infusion and to use highly effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of active or chronic infection, including severe acute respiratory syndrome&#xD;
             coronavirus 2 (SARS-CoV-2), or any immunosuppressive disorder&#xD;
&#xD;
          2. Contraindication to using glucocorticosteroids GCS, including a diagnosis of glaucoma&#xD;
             or untreated osteoporosis&#xD;
&#xD;
          3. Active malignancy (except non-melanoma skin cancer) autoimmune, metabolic (i.e.,&#xD;
             diabetes), hematologic, cardiac, or renal disease that is of clinical significance&#xD;
             defined as requiring regular medical attention and treatment&#xD;
&#xD;
          4. Prior gene therapy treatment&#xD;
&#xD;
          5. Prior use of attenuated androgens in the last 1 year prior the study&#xD;
&#xD;
          6. History or current clinically relevant liver disease (eg, nonalcoholic steatohepatitis&#xD;
             [NASH], or chronic viral hepatitis B or C [HBV or HCV] or autoimmune hepatitis)&#xD;
&#xD;
          7. Have a history or are at risk for clinically significant thromboembolic events (TEE) ,&#xD;
             or known underlying risk factor for thrombosis including thrombotic microangiopathy&#xD;
             (TMA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Specialist</last_name>
    <phone>1-800-983-4587</phone>
    <email>medinfo@bmrn.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <keyword>Hereditary Angioedema</keyword>
  <keyword>Gene Therapy</keyword>
  <keyword>331-201</keyword>
  <keyword>331</keyword>
  <keyword>Haermony</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

